Core Technology

  • Proven, tunable early Programmed Dismantling (3 months) followed by a fast and safe Resorption (24 months): unique proprietary PLA polymer formula
  • Safe Delivery and Tracking: outstanding scaffold retention enabled by patented 1-to-1 mapping™ crimping technologyGood
  • Apposition and Radial Force without Fracture: natural polymer chain orientation combined with controlled physical crosslinking enabled through patented transformation process
  • Robust GLP preclinical trial track record with proven vessel enlargement after 6 months sustaining the Positive Remodeling response; safety data > 250 implantations, 36 months follow up
  • First In Man ARTDIVA trial confirmed device performances


Publications :

Lafont et al, Restenosis after experimental angioplasty. Intimal, medial, and Adventitial changes associated with constrictive remodeling. Circ Res. 1995 Jun;76(6):996-1002

Lafont A et al, Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation. 1999 Sep 7;100(10):1109-15

Virmani R et al, Drug eluting stents: are human and animal studies comparable? Heart. 2003 Feb;89(2):133-8. Review.

Durand, et al, Head-to-head comparison of a drug-free early programmed dismantling polylactic acid bioresorbable scaffold and a metallic stent in the porcine coronary artery: six-month angiography and optical coherence tomographic follow-up study. Circ Cardiovasc Interv. 2014 Feb;7(1):70-9